Justin Zelin
Stock Analyst at BTIG
(1.42)
# 3,506
Out of 4,967 analysts
39
Total ratings
25%
Success rate
-1.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $43 → $56 | $16.11 | +247.61% | 2 | Aug 5, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $64 → $20 | $2.76 | +624.64% | 2 | Jul 7, 2025 | |
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.38 | +152.10% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $20.89 | +101.05% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.44 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $25.48 | +143.33% | 2 | Jul 9, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.75 | +585.71% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $7.41 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $27.49 | +354.71% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $9.22 | +192.84% | 1 | Nov 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.53 | +52,187.58% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $32.24 | +182.26% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.73 | +1,261.66% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.30 | +595.65% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $9.19 | +302.61% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $34.22 | +163.00% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $7.95 | +289.94% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $56.38 | -72.51% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.88 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $2.30 | +334.78% | 3 | Nov 16, 2022 |
Syndax Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $43 → $56
Current: $16.11
Upside: +247.61%
Jasper Therapeutics
Jul 7, 2025
Maintains: Buy
Price Target: $64 → $20
Current: $2.76
Upside: +624.64%
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $20.89
Upside: +101.05%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.44
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $25.48
Upside: +143.33%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.75
Upside: +585.71%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.41
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $27.49
Upside: +354.71%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $9.22
Upside: +192.84%
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.53
Upside: +52,187.58%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $32.24
Upside: +182.26%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.73
Upside: +1,261.66%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.30
Upside: +595.65%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $9.19
Upside: +302.61%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $34.22
Upside: +163.00%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $7.95
Upside: +289.94%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $56.38
Upside: -72.51%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.88
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $2.30
Upside: +334.78%